PALI
Palisade BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
PALI vs peer average
79/100
PALI vs. peer average (B vs. D)
Grade spread
A 1 · B 1 · C 2 · D 1 · F 5
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
SYRE is the first available peer comparator.
Indication-and-stage comparator only: Spyre reported Phase 2 ulcerative-colitis induction data, but its antibody programs differ from PALI-2108’s oral PDE4 prodrug. Its pipeline and funding also preclude a direct valuation multiple. Source: https://ir.spyre.com/news-releases/news-release-details/spyre-announces-potential-best-class-spy002-anti-tl1a-part
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PALI
Palisade Bio
SYRE
Spyre Therapeutics
Grade
B
F
Momentum
85
84
Value
41
41
Sentiment
78
13
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs SYRE
PALI / SYRE
Grade Position
Above peers
PALI vs. peer average (B vs. D)
79/100
Momentum
85
PALIValue
41
PALISentiment
78
PALIRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PALI
SYRE is the first peer returned for this comparison set.